Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 1.1% - What's Next?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s share price traded down 1.1% during mid-day trading on Tuesday . The company traded as low as $5.88 and last traded at $6.06. 5,260,868 shares traded hands during mid-day trading, a decline of 79% from the average session volume of 25,323,674 shares. The stock had previously closed at $6.13.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on RXRX. KeyCorp decreased their target price on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 8th. Leerink Partners decreased their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a report on Friday, February 28th. Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $8.25.

Recursion Pharmaceuticals Trading Up 5.1 %

The company has a market capitalization of $2.51 billion, a PE ratio of -4.08 and a beta of 0.85. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock's fifty day moving average price is $7.57 and its two-hundred day moving average price is $7.03.

Remove Ads

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its earnings results on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business had revenue of $4.60 million for the quarter, compared to the consensus estimate of $19.04 million. During the same quarter in the prior year, the company earned ($0.42) EPS. Recursion Pharmaceuticals's revenue was down 57.8% compared to the same quarter last year. Sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Institutional Trading of Recursion Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in Recursion Pharmaceuticals by 40.1% during the fourth quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock valued at $229,908,000 after buying an additional 9,737,196 shares during the period. Softbank Group CORP. purchased a new position in Recursion Pharmaceuticals during the 4th quarter valued at about $99,152,000. State Street Corp boosted its stake in Recursion Pharmaceuticals by 47.1% during the third quarter. State Street Corp now owns 12,870,272 shares of the company's stock worth $84,815,000 after acquiring an additional 4,120,685 shares in the last quarter. Novo Holdings A S bought a new position in shares of Recursion Pharmaceuticals during the fourth quarter valued at approximately $68,375,000. Finally, FMR LLC lifted its holdings in shares of Recursion Pharmaceuticals by 2.1% during the third quarter. FMR LLC now owns 8,363,530 shares of the company's stock valued at $55,116,000 after purchasing an additional 170,810 shares during the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.